Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2...
October 19 2020 - 6:00PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that it will have two data presentations
at the Infectious Disease Society of America (IDSA)
IDWeek™ 2020 taking place virtually from October 21 - 25,
2020. The two data presentations will include a poster presentation
of the results of SURE-2 in complicated urinary tract infections
(cUTI) as well as a late breaker oral abstract presentation of the
results from SURE-1 in uncomplicated urinary tract infections
(uUTI). In June 2020, the Company announced top-line data from
the SURE-1 trial demonstrating that oral sulopenem was
statistically superior to oral ciprofloxacin in the treatment of
patients with uUTI caused by a quinolone non-susceptible pathogen.
Presentation Title: Efficacy
and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral
Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract
Infections (uUTI) in Adult Women: Results from the SURE-1
TrialSession
Name: STIs &
UTIsPresenter: Michael DunneDate:
October 21, 2020
Title: Efficacy and Safety of Intravenous
Sulopenem Followed by Oral Sulopenem etzadroxil/ Probenecid Versus
Intravenous Ertapenem Followed by Oral Ciprofloxacin or
Amoxicillin-clavulanate in the Treatment of Complicated Urinary
Tract Infections (cUTI): Results from the SURE-2
TrialPoster Session: : STIs &
UTIsPresenter: Michael DunneDate:
October 21, 2020
Abstracts are accessible via the IDWeek™ website. Poster
presentations may be accessed through the Company’s website on the
“Publications: Posters & Presentations” page under the “Our
Science” tab following their completion.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside the Company’s
control, including the uncertainties inherent in the initiation and
conduct of clinical trials, availability and timing of
data from clinical trials, changes in regulatory requirements or
decisions of regulatory authorities, the Company’s ability to apply
for regulatory approval and the timing of approval of any
submission, changes in public policy or legislation,
commercialization plans and timelines, if sulopenem is approved,
the actions of third-party clinical research organizations,
suppliers and manufacturers, the accuracy of the Company’s
expectations regarding how far into the future the Company’s cash
on hand will fund the Company’s ongoing operations, the sufficiency
of the Company’s cash resources and the Company’s ability to
continue as a going concern, the impact of COVID-19 and related
responsive measures thereto, the Company’s ability to maintain
listing on the Nasdaq Stock Market, risks and uncertainties
concerning the outcome, impact, effects and results of the
Company’s evaluation of corporate, organizational, strategic,
financial and financing alternatives, including the terms, timing,
structure, value, benefits and costs of any corporate,
organizational, strategic, financial or financing alternative and
the Company’s ability to complete one at all, the price of the
Company’s securities and other factors discussed under the caption
“Risk Factors” in its most recently filed Quarterly Report on Form
10-Q, and other documents filed with the SEC from time to time.
Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
Investor Contact:Judy Matthews Chief
Financial Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024